Sharad Goyal1, Ann W Silk2, Sibo Tian1, Janice Mehnert2, Shabbar Danish3, Sinthu Ranjan1, Howard L Kaufman3. 1. Department of Radiation Oncology, Rutgers Cancer Institute of New Jersey and Rutgers Robert Wood Johnson Medical School, New Brunswick. 2. Division of Medical Oncology, Rutgers Cancer Institute of New Jersey and Rutgers Robert Wood Johnson Medical School, New Brunswick. 3. Division of Surgical Oncology, Rutgers Cancer Institute of New Jersey and Rutgers Robert Wood Johnson Medical School, New Brunswick.
Abstract
IMPORTANCE: The treatment of multiple brain metastases (MBM) from melanoma is controversial and includes surgical resection, stereotactic radiosurgery (SRS), and whole-brain radiation therapy (WBRT). Several new classes of agents have revolutionized the treatment of metastatic melanoma, allowing some subsets of patients to have long-term survival. Given this, management of MBM from melanoma is continually evolving. OBJECTIVE: To review the current evidence regarding the treatment of MBM from melanoma. EVIDENCE REVIEW: The PubMed database was searched using combinations of search terms and synonyms for melanoma, brain metastases, radiation, chemotherapy, immunotherapy, and targeted therapy published between January 1, 1995, and January 1, 2015. Articles were selected for inclusion on the basis of targeted keyword searches, manual review of bibliographies, and whether the article was a clinical trial, large observational study, or retrospective study focusing on melanoma brain metastases. Of 2243 articles initially identified, 110 were selected for full review. Of these, the most pertinent 73 articles were included. FINDINGS: Patients with newly diagnosed MBM can be treated with various modalities, either alone or in combination. Level 1 evidence supports the use of SRS alone, WBRT, and SRS with WBRT. Although the addition of WBRT to SRS improves the overall brain relapse rate, WBRT has no significant impact on overall survival and has detrimental neurocognitive outcomes. Cytotoxic chemotherapy has largely been ineffective; targeted therapies and immunotherapies have been reported to have high response rates and deserve further attention in larger clinical trials. Further studies are needed to fully evaluate the efficacy of these novel regimens in combination with radiation therapy. CONCLUSIONS AND RELEVANCE: At this time, the standard management for patients with MBM from melanoma includes SRS, WBRT, or a combination of both. Emerging data exist to support the notion that SRS in combination with targeted therapies or immune therapy may obviate the need for WBRT; prospective studies are required to fully evaluate the efficacy of these novel regimens in combination with radiation therapy.
IMPORTANCE: The treatment of multiple brain metastases (MBM) from melanoma is controversial and includes surgical resection, stereotactic radiosurgery (SRS), and whole-brain radiation therapy (WBRT). Several new classes of agents have revolutionized the treatment of metastatic melanoma, allowing some subsets of patients to have long-term survival. Given this, management of MBM from melanoma is continually evolving. OBJECTIVE: To review the current evidence regarding the treatment of MBM from melanoma. EVIDENCE REVIEW: The PubMed database was searched using combinations of search terms and synonyms for melanoma, brain metastases, radiation, chemotherapy, immunotherapy, and targeted therapy published between January 1, 1995, and January 1, 2015. Articles were selected for inclusion on the basis of targeted keyword searches, manual review of bibliographies, and whether the article was a clinical trial, large observational study, or retrospective study focusing on melanoma brain metastases. Of 2243 articles initially identified, 110 were selected for full review. Of these, the most pertinent 73 articles were included. FINDINGS:Patients with newly diagnosed MBM can be treated with various modalities, either alone or in combination. Level 1 evidence supports the use of SRS alone, WBRT, and SRS with WBRT. Although the addition of WBRT to SRS improves the overall brain relapse rate, WBRT has no significant impact on overall survival and has detrimental neurocognitive outcomes. Cytotoxic chemotherapy has largely been ineffective; targeted therapies and immunotherapies have been reported to have high response rates and deserve further attention in larger clinical trials. Further studies are needed to fully evaluate the efficacy of these novel regimens in combination with radiation therapy. CONCLUSIONS AND RELEVANCE: At this time, the standard management for patients with MBM from melanoma includes SRS, WBRT, or a combination of both. Emerging data exist to support the notion that SRS in combination with targeted therapies or immune therapy may obviate the need for WBRT; prospective studies are required to fully evaluate the efficacy of these novel regimens in combination with radiation therapy.
Authors: Caroline Robert; Boguslawa Karaszewska; Jacob Schachter; Piotr Rutkowski; Andrzej Mackiewicz; Daniil Stroiakovski; Michael Lichinitser; Reinhard Dummer; Florent Grange; Laurent Mortier; Vanna Chiarion-Sileni; Kamil Drucis; Ivana Krajsova; Axel Hauschild; Paul Lorigan; Pascal Wolter; Georgina V Long; Keith Flaherty; Paul Nathan; Antoni Ribas; Anne-Marie Martin; Peng Sun; Wendy Crist; Jeff Legos; Stephen D Rubin; Shonda M Little; Dirk Schadendorf Journal: N Engl J Med Date: 2014-11-16 Impact factor: 91.245
Authors: May N Tsao; Nancy S Lloyd; Rebecca K S Wong; Eileen Rakovitch; Edward Chow; Normand Laperriere Journal: Cancer Treat Rev Date: 2005-06 Impact factor: 12.111
Authors: Paul D Brown; Stephanie Pugh; Nadia N Laack; Jeffrey S Wefel; Deepak Khuntia; Christina Meyers; Ali Choucair; Sherry Fox; John H Suh; David Roberge; Vivek Kavadi; Soren M Bentzen; Minesh P Mehta; Deborah Watkins-Bruner Journal: Neuro Oncol Date: 2013-08-16 Impact factor: 12.300
Authors: Michael A Davies; Ping Liu; Susan McIntyre; Kevin B Kim; Nicholas Papadopoulos; Wen-Jen Hwu; Patrick Hwu; Agop Bedikian Journal: Cancer Date: 2010-10-19 Impact factor: 6.860
Authors: Lisa M Guirguis; James C Yang; Donald E White; Seth M Steinberg; David J Liewehr; Steven A Rosenberg; Douglas J Schwartzentruber Journal: J Immunother Date: 2002 Jan-Feb Impact factor: 4.456
Authors: Reinhard Dummer; Simone M Goldinger; Christian P Turtschi; Nina B Eggmann; Olivier Michielin; Lada Mitchell; Luisa Veronese; Paul René Hilfiker; Lea Felderer; Jeannine D Rinderknecht Journal: Eur J Cancer Date: 2013-11-29 Impact factor: 9.162
Authors: Panagiotis Mastorakos; Zhiyuan Xu; James Yu; Judith Hess; Jack Qian; Ajay Chatrath; Davis G Taylor; Douglas Kondziolka; Ronald Warnick; Veronica Chiang; Jason Sheehan Journal: Neurosurgery Date: 2019-04-01 Impact factor: 4.654
Authors: Michael C LeCompte; Emory McTyre; Adrianna Henson; Michael Farris; Catherine Okoukoni; Christina K Cramer; Pierre Triozzi; Jimmy Ruiz; Kounosuke Watabe; Hui-Wen Lo; Michael T Munley; Adrian W Laxton; Stephen B Tatter; Xiaobo Zhou; Michael Chan Journal: Cureus Date: 2017-12-11
Authors: Christopher Alvarez-Breckenridge; Anita Giobbie-Hurder; Corey M Gill; Mia Bertalan; Jackson Stocking; Alexander Kaplan; Naema Nayyar; Donald P Lawrence; Keith T Flaherty; Helen A Shih; Kevin Oh; Tracy T Batchelor; Daniel P Cahill; Ryan Sullivan; Priscilla K Brastianos Journal: Oncologist Date: 2019-02-22
Authors: Gautham Gampa; Shruthi Vaidhyanathan; Brynna-Wilken Resman; Karen E Parrish; Svetomir N Markovic; Jann N Sarkaria; William F Elmquist Journal: Curr Pharmacol Rep Date: 2016-11-09
Authors: Filipe Martins; Luis Schiappacasse; Marc Levivier; Constantin Tuleasca; Michel A Cuendet; Veronica Aedo-Lopez; Bianca Gautron Moura; Krisztian Homicsko; Adrienne Bettini; Gregoire Berthod; Camille L Gérard; Alexandre Wicky; Jean Bourhis; Olivier Michielin Journal: J Neurooncol Date: 2019-12-14 Impact factor: 4.130